

February 22, 2008

## **Astellas Receives a Positive CHMP Opinion for EU Marketing Authorization for Mycamine<sup>®</sup>**

Japan, February 22, 2008 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, "Astellas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for Mycamine<sup>®</sup> (generic name: micafungin sodium) on February 21 (local time).

Astellas' EU subsidiary submitted a Marketing Authorization Application for Mycamine in April 2006 and has been reviewed under the centralized procedure. The CHMP based its positive opinion on its review of the comprehensive data package for Mycamine. Mycamine was granted the positive opinion for the treatment of invasive candidiasis; prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia, and in adolescents aged 16 years or older and adults for the treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate. Following the CHMP's positive opinion, the application will be reviewed by the European Commission which has the authority to grant marketing authorizations for the European Union. Astellas expects to be granted the marketing authorization in May 2008.

Mycamine has been available in the domestic market with the brand name of Funguard<sup>®</sup> for Infusion since December 2002. Funguard for Infusion has established its therapeutic efficacy against fungal infections caused by *Aspergillus* and *Candida* and safety through therapeutic results. MYCAMINE<sup>®</sup> has been commercially available in the US market since May 2005 for the treatment of patients with esophageal candidiasis and prophylaxis of *Candida* infections in patients undergoing hematopoietic stem cell transplantation and is approved for the treatment of patients with Candidemia, Acute Disseminated Candidiasis, *Candida* Peritonitis and Abscesses in January 2008. Astellas is expecting that Mycamine will contribute to the treatment of fungal infections throughout Europe.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 <a href="http://www.astellas.com">http://www.astellas.com</a>